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Evidence shows that inﬂammatory and immune processes within the brain might account for the pa-
thophysiology of epilepsy. Therefore, developing new antiepileptic drugs that can modulate seizures
through mechanisms other than traditional drugs is required for the treatment of refractory epilepsy.
This study aims to determine the relationship between brain inﬂammation and epilepsy, to examine the
contribution of some biochemical parameters involved in brain inﬂammation, and to address the effect of
pharmacological interventions using some anti-inﬂammatory and immunomodulatory drugs in an ex-
perimental epilepsy model. Adult male rats were divided into seven groups of 20. G1 was the normal,
non-treated control. G2 was the epileptic, non-treated group. G3–G7 were treated with celecoxib,
methotrexate, azathioprine, dexamethasone, and valproate, respectively, for a period of three weeks.
Induction of status epilepticus (SE) by Li-pilocarpine was performed on groups G2–G7. EEG tracing was
conducted, and inﬂammatory mediators (brain and serum IL-1ß, IL 6, PGE2, HSP70, TGF-β2, and IFNγ)
were measured. The induction of SE increased the amplitude and frequency of EEG tracing and in-
ﬂammatory mediators more than in the normal control group. Treatments of epileptic rats reduced the
frequency and amplitude of EEG tracing and signiﬁcantly decreased the levels of inﬂammatory mediators
in some treated rats compared to G2. These ﬁndings demonstrate that some anti-inﬂammatory and
immunomodulatory drugs can lower the frequency and amplitude of seizures and reduce some in-
ﬂammatory mediators in epilepsy treatments, strengthening the possibility that targeting these im-
munological and inﬂammatory pathways may represent another effective therapeutic approach to pre-
venting epileptic seizures.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Epilepsy is a neurological disorder identiﬁed by recurrentB.V. This is an open access article u
holamine; IFN-γ, interferon-
IL-1Ra, interleukin-1 receptor
F-kB, nuclear factor kappaB;
lood mononuclear cells; PTZ,
tus epilepticus; SNS, sympa-
NFα, tumor necrosis factor α;
ology and Toxicology, Faculty
i Arabia.
m).seizures that are often accompanied by cognitive deﬁcits and
mood disorders (Devinsky, 2004; Jones et al., 2008). Because sei-
zures are the result of uncontrollable neural excitation in the brain,
epilepsy has primarily been considered a neurological disease.
Most current antiepileptic drugs (AEDs) control neuronal excit-
ability through a direct effect on ion channels. In fact, AEDs have at
least two major setbacks. First, 20–30% of patients have poor sei-
zure control that becomes medically intractable, even with opti-
mal AED therapy. Second, AEDs generally depress the central
nervous system (CNS) and impose marked inhibitory effects on
cognitive development. Therefore, the development of new AEDs
that can modulate seizures through another mechanism is re-
quired for refractory epilepsy treatment (Shimada and Takemiya,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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In the last decade, clinical and experimental reports on the
pathophysiology of epilepsy and seizures have extensively sup-
ported the hypothesis that the immune system and inﬂammatory
processes inside the brain may encompass common and sig-
niﬁcant mechanisms (Riazi et al., 2010; Vezzani and Granata,
2005; Vezzani et al., 2011). The primary understanding of the
promising role of inﬂammation in epilepsy has resulted from
clinical data demonstrating that steroids and other anti-in-
ﬂammatory treatments have produced anticonvulsant activity in
some epilepsies resistant to AEDs (Wheless et al., 2007). Evidence
was derived from febrile seizures (Dube et al., 2007), which
usually concur with, and are caused by, an increase in levels of
proinﬂammatory agents (Dinarello, 2004). Inﬂammation resulting
from brain-damaging conditions, such as status epilepticus, trau-
ma, stroke, infection, and hyperthermia, is accompanied by acute
attacks of seizures and a high risk of developing epilepsy (Bartfai
et al., 2007; Pitkanen and Sutula, 2002). Data from some patients
having seizure disorders with activated immune systems, an in-
creased occurrence of seizures in autoimmune disorders, and the
detection of limbic encephalitis as a reason for their epilepsy (Bien
et al., 2007; Vincent and Bien, 2008) led to the hypothesis that
inﬂammatory and immune mechanisms play critical roles in some
types of epilepsy (Aarli, 2000; Devinsky, 2004).
Preclinical and clinical studies have proven an intricate re-
lationship between seizures and the immune method that is
mediated via cytokines (Youn et al., 2013). Numerous in-
ﬂammatory intermediaries have been found in brain tissues sur-
gically resected from patients with refractory epilepsies, such as
temporal lobe epilepsy (TLE) and epilepsy related to cortical dys-
plasia (Devinsky, 2004; Shimada and Takemiya, 2014). Some of
these inﬂammatory mediators include IL1B, IL6, IFNγ (Uludag
et al., 2015), HSP70 (Turturici et al., 2011), PGE2 (Salvadori et al.,Group1
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Evidence that the immune system and inﬂammation are in-
volved in the pathophysiology of epilepsy has raised the prospect
of new therapeutic approaches for treating epilepsy and seizures
that are resistant to currently available AEDs, and targeting in-
ﬂammation-related pathways with anti-inﬂammatory and im-
munotherapies could have some advantages compared with using
antiepileptic medications alone (Roberts and Goralski, 2008).
The aims of this study were to determine the relationship be-
tween brain inﬂammation and epilepsy, to examine the con-
tributions of some biochemical parameters involved in brain in-
ﬂammation, and to address the effect of pharmacological inter-
ventions using some anti-inﬂammatory and immunomodulatory
drugs in an experimental epilepsy model.
The experimental design is illustrated in Fig. 1.2. Results
Status epilepticus occurred in 100% of rats. The mortality rate
ranged from 5% to 10% in different groups.
2.1. EEG tracing, Fig. 2(a–g)
The normal rat group (G1) (Fig. 2a) featured a normal EEG re-
cord with background activity in the range of 11–12 Hz alpha
waves that were mildly synchronous, well-organized, and of nor-
mal amplitude (from 20 to 80 mV). No focal sharp or spike wave
activity was detectable.
The induction of SE in rats (Fig. 2b) produced EEGs of high
amplitude (from 200 to 400 mV) with superimposed, mildly fast,
and poly spike waves and slow background activity (6–7 Hz) in
the theta range. This EEG trace denotes the development of 
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Fig. 2. EEG Tracing in Different Groups. Fig. 2a There was a normal EEG record with background activity in the range of 11–12 Hz alpha waves that were mildly synchronous,
well-organized, and of normal amplitude (from 20 to 80 mV). No focal sharp or spike waves activity was detectable. The induction of SE in rats (Fig. 2b) produced EEGs of high
amplitude (from 200 to 400 mV) with superimposed, mildly fast, and poly spike waves and slow background activity (6–7 Hz) in the theta range. This EEG trace denotes the
development of epileptogenic clonic activity in the examined group. Fig. 2c EEGs showed a lower amplitude (100–160 mV) and faster background activity, when compared
with the epileptic trace of the normal alpha range (11–12 Hz). Fig. 2d showed the least improvement from the epileptic trace with amplitude (80–180 mV) and a slow
background theta activity (6–7 Hz). Fig. 2e showed EEG tracing with a tendency for an amplitude improvement (60–170 mV) from the epileptic trace. This goes back to the
normal alpha range frequency (9–10 Hz). Fig. 2f showed an improvement in the EEG background activity more than the epileptic trace in the form of wave amplitude (120–
190 mV), with return to the normal alpha range frequency (10–11 Hz). Fig. 2g showed EEG records with background activity in the alpha range (9–10 Hz) that were mildly
synchronous, well organized, and a wave amplitude (100–180 mV). No focal sharp or spike wave activity was detectable.
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In celecoxib-treated rats (Fig. 2c), the induction of epilepsy
resulted in EEGs that showed faster and lower amplitudes (100–
160 mV) and background activity, when compared with the epi-
leptic trace of the normal alpha range (11–12 Hz).
The EEG tracing in the methotrexate-treated epileptic group
(G4) (Fig. 2d) showed the least improvement from the epileptic
trace, with amplitude (80–180 mV) and a slow background theta
activity (6–7 Hz).
The azathioprine-treated epileptic group (G5) (Fig. 2e) showed
EEG tracings with a tendency toward amplitude improvement
(60–170 mV) from the epileptic trace. This goes back to the normal
alpha range frequency (9–10 Hz).
The injection of dexamethasone in the epileptic rats (G6)
(Fig. 2f) showed an improvement in the EEG background activity
more so than the epileptic trace in the form of wave amplitude
(120–190 mV), with a return to the normal alpha range frequency
(10–11 Hz).
The injection of valproate in epileptic rats (G7) (Fig. 2g) showed
EEG records with background activity in the alpha range (9–10 Hz)that were mildly synchronous and well-organized as well as wave
amplitude of 100–180 mV. No focal sharp or spike wave activity
was detectable.
2.2. Serum and brain inﬂammatory mediators (Tables 1 and 2)
In the present study, the induction of epilepsy by lithium/pi-
locarpine (Group 2) in rats signiﬁcantly increased (po0.001) brain
IL-1B, IL-6, and HSP70 and brain and serum PG E2, compared to the
normal control (Group 1).
In celecoxib-treated rats (Group 3), the induction of epilepsy
produced signiﬁcant decreases (po0.001) in brain IL-6, serum and
brain PG E2, and serum IFN-gamma, compared to epileptic non-
treated rats (Group 2).
Treatment with methotrexate (Group 4) signiﬁcantly decreased
(po0.001) brain IL-6, HSP70, and TGF-B2 as well as serum PG E2 and
IFN-gamma, when compared to epileptic non-treated rats (Group 2).
In comparison with G2, azathioprine treatment (Group 5) sig-
niﬁcantly decreased (po0.001) brain IL-6 and HSP70 and serum
PG E2 and IFN-gamma.
Table 1
Serum Inﬂammatory Mediators in Different Study Groups.
Groups (n¼16) IL-1β pg/ml IL-6 pg/ml PGE2 pg/ml HSP70 pg/ml TGF-β2 pg/ml IFN-γ pg/ml
Normal 200.9972.89 12.6371.45 172.1979.7 145.5177.20 70.4575.52 292.21719.88
Epileptic control 204.775.57 15.5475.53 215.06721.5# 145.8577.33 72.8577.39 318.45717.0
Celecoxib treated 202.2874.59 15.7073.44 151.1775.84þ 145.7776.68 66.8278.43 258.25723.4þ
Methotrexate treated 204.1175.31 18.5971.99 167.39723.48þ 148.22715.58 66.0775.55 276.1470.13þ
Azathioprine treated 206.9713.04 22.4373.98 152.7779.37þ 144.3876.21 66.0376.47 261.33723.91þ
Dexamethasone treated 200.5572.42 18.9574.18 172.17714.45þ 137.3774.23 68.8674.76 311.5978.80
Valproate treated 203.6574.79 20.4173.84 163.5477.59þ 137.6575.96 64.4872.98 270.67711.72þ
Table 2
Brain Inﬂammatory Mediators in Different Study Groups.
Groups (n¼16) IL-1β pg/ml IL-6 pg/ml PGE2 pg/ml HSP70 pg/ml TGF-β2 pg/ml IFN-γ pg/ml
Normal 292.59714.7 41.3074.52 236.89726.2 202.94þ14.2 122.6275.11 334.61718.12
Epileptic control 321.9722.4# 54.1073.98# 284.3718.6# 267.19þ25.6# 133.4878.69 358.83721.8
Celecoxib treated 309.50719.51 32.0473.83þ 238.1745.78þ 266.53þ25.42 122.3479.93 355.89715.6
Methotrexate treated 295.00716.28 34.8574.49þ 268.92715.12 188.41þ10.58þ 112.14713.46þ 348.3770.08
Azathioprine treated 298.75712.79 44.6076.16þ 308.64732.20 215.55þ11.74þ 120.8774.96 354.49721.20
Dexamethasone treated 281.64722.86þ 36.5574.39þ 224.64729.73þ 266.27þ22.52 128.30711.31 362.44737.8
Valproate treated 295.80717.51 42.1273.49þ 244.5278.70 284.52þ18.06 125.7677.24 355.23716.09
All values are expressed as Mean7SD; SD: Standard deviation; po0.05 is considered signiﬁcant.
n: number of animals per group, pg: picogram, ml: milliliter.
IL-1ß: Interleukin 1-ß, IL 6: Interleukin 6, PGE2: Prostaglandin E2, HSP70: Heat shock protein 70, TGF-β2: Transforming growth factor β2, IFNγ: Interferon gamma.
# Signiﬁcant from normal non-treated control.
þ Signiﬁcant from epileptic non-treated control.
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brain IL-1B, IL-6, PG E2, and serum PG E2, when compared with
epileptic Group 2.
In valproate-treated rats (Group 7), when compared with the
epileptic non-treated Group 2, the induction of epilepsy sig-
niﬁcantly reduced (po0.001) brain IL-6 and serum PG E2 and IFN-
gamma (Tables 1 and 2).3. Discussion
In the present study, the induction of epilepsy by lithium/pi-
locarpine in rats produced an increase in the frequency and am-
plitude of the EEG tracing.
These results are in agreement with the ﬁndings of Morrisett
et al. (1987), who demonstrated that the administration of pilo-
carpine after lithium led to spike and seizure activities in 100% of
treated rats. Pilocarpine injection induces EEG and behavioral
limbic changes and status epilepticus, as recorded from the hip-
pocampus and the cortex. Pilocarpine-induced SE causes massive
neuronal damage when examined at 24–72 h. Pretreatment with
LiCl seems to potentiate the effect of pilocarpine, since lithium, in
combination with a lower dose of pilocarpine, induces the most
consistent SE in rats. The onset and termination of SE are de-
termined by behavioral seizures and EEG changes (Marchi et al.,
2009; Reddy and Kuruba, 2013). The lithium-pilocarpine rat model
may prove valuable in the study of status epilepticus for a number
of reasons. First, these seizures replicate generalized human epi-
lepsy models. Second, the severity and refractory nature of this
model indicates that lithium and pilocarpine are valuable for the
development of new anticonvulsant agents. Finally, the delayed
and consistent degree of status epilepticus is a useful tool for
metabolic, neurochemical, and neuroanatomical studies of the
extended seizure activity sequelae (Morrisett et al., 1987; Vezzani
and Granata, 2005).
Increased inﬂammatory mediators during epilepsy in the pre-
sent study coincide with other studies. These studies suggested
that brain pro-inﬂammatory conditions, developed after CNSproblems such as SE, might play a role in epilepsy development
(Gorter et al., 2006; Vezzani, 2014). Studies on experimental
models of induced seizures in rodents demonstrated a rapid onset
of inﬂammatory response and the release of proinﬂammatory
mediators that contribute to the mechanisms of ictogenesis from
activated glia and neurons (Riazi et al., 2010; Vezzani and Granata,
2005; Vezzani et al., 2011). Seizure activation results in neuronal
cell loss and the destruction of the BBB (Ravizza et al., 2008), and
the breakdown of the BBB can increase neuronal excitability by
enhancing inﬂammatory responses in the brain (Heinemann et al.,
2012; Ransohoff et al., 2003). Uludag et al. (2015) demonstrated
that interleukin IL-1β, IL-6, and TNF-α inﬂammatory cytokine
genes are up-regulated and activated in astrocytes and microglia
after seizures. Also, IL-6 concentration increased chronically and
was found to be more noticeable in CSF than in plasma, especially
in TLE. Accordingly, the synthesis of IL-6 was thought to occur
principally within the CNS (Billiau et al., 2007), which coincides
with the results of the present study. The increased prostaglandins
after epilepsy induction in this study is conﬁrmed by Takemiya
et al. (2010), who noted that epileptic seizures rapidly induce COX-
2 in excitatory neurons and increase brain PGE2 levels. COX-2-
coupled PGE2 production can promote seizures through mechan-
isms that drive epileptogenesis, such as the stimulation of in-
ﬂammatory processes, a marked contribution in the reduction of
seizure threshold with increases following seizures, and neuronal
cell death (Salvadori et al., 2012).
Increased brain heat shock protein 70 (HSP 70) in this study
coincides with studies that proved that HSPs can induce the innate
immune system through their interactions with cell surface re-
ceptors, leading to the expression of proinﬂammatory cytokines,
chemokines (Asea et al., 2000), and the activation of dendritic
cells (Floto et al., 2006). HSPs are stress markers in temporal lobe
epilepsy and are induced in response to some neurological
diseases. There is a positive correlation between serum levels
of HSP70 and the duration of epilepsy, hippocampal degeneration,
and memory dysfunction, indicating that it can be used as
a biomarker for stress-related neuronal damage (Chang et al.,
2012).
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environment due to BBB gaps stimulates the transforming growth
factor beta (TGFβ) receptor-mediated signaling cascade in astro-
cytes (Cacheaux et al., 2009). The pleiotropic effects of the TGF-β
signaling pathway produce a reasonable mechanism for epilepto-
genesis following brain injury and promote a speciﬁc therapeutic
target (Weissberg et al., 2015). Proinﬂammatory cytokine levels
(IL-6 and IFN-γ) are elevated in the peripheral blood of patients
with epilepsy (Mao et al., 2013). IFN-γ plays an essential role in the
development of the brain's excitatory seizure pathways, and it has
been associated with the development of limbic seizures (Getts
et al., 2007).
Consequently, epileptic seizures and inﬂammatory mediators can
reinforce each other, forming a positive feedback loop (Shimada and
Takemiya, 2014). These ﬁndings increase the probability that target-
ing these inﬂammatory pathways may serve as a useful therapeutic
approach to preventing seizures (Morin-Brureau et al., 2011).
In the present study, celecoxib (cyclooxygenase-2 inhibitor)
showed a signiﬁcant decrease in some brain and serum mediators
and the frequency and amplitude of EEG tracing, compared to the
epileptic non-treated group. These data are consistent with the
ﬁndings of the study, which demonstrated that celecoxib reduced
inﬂammatory mediators, decreased epileptic activities, and in-
creased the seizure threshold (Schlichtiger et al., 2010).
Treatments with methotrexate, azathioprine, and dex-
amethasone showed similar trends and decreased some brain and
serum mediators and the EEG tracing. These results support the
notion that anti-inﬂammatory and immunosuppressive therapies
may be necessary in epilepsy and can produce better outcomes if
combined with neuronal targeting.
ACTH and glucocorticoids have been used successfully in the
treatment of some types of epilepsy (Suleiman et al., 2011). Pilo-
carpine-induced seizures cause cerebrovascular changes (Leite
et al., 2002) and induce seizures by an unpredicted immunologic
activation mediated by speciﬁc receptors and adhesion molecules
(Marchi et al., 2009). Corticosteroids target these molecules,
causing their depletion, which appears to protect against clinical
or pilocarpine-induced seizures. Corticosteroids have an intense
effect on human and rodent BBB permeability (Vezzani and
Granata, 2005); therefore, corticosteroids oppose BBB leakage and
seizures produced by the activation of the immune system.
Immunotherapy options for the treatment of epilepsy include
different medications, and randomized controlled trials of im-
munotherapy in presumed autoimmune epilepsy are needed to
provide further support for the rapid use of immunotherapy in
patients with immune-mediated epilepsy (Melvin and Huntley
Hardison, 2014; Ozkara and Vigevano, 2011).
In the present study, valproate, used as an example of a tradi-
tional AED, produced a signiﬁcant decrease in some serum and
brain inﬂammatory mediators and frequency and amplitude of
EEG recordings from the epileptic non-treated group. These results
are supported by Himmerich and Bartsch’s (2014) results. They
demonstrated that valproic acid decreased the production of var-
ious cytokines, namely IL-1β, IL-2, IL-4, IL-6, IL-17, and TNF-α.
Valproic acid has antioxidative and anti-inﬂammatory properties,
which are consistent with decrease in mediators’ production. It
also has protective effects against various types of ischemia and
reperfusion injury, as well as inﬂammatory diseases (Suda et al.,
2013).
In conclusion, these ﬁndings demonstrated that some anti-in-
ﬂammatory and immunomodulatory drugs can lower the fre-
quency and amplitude of seizures and reduce some inﬂammatory
mediators during epilepsy treatment. This strengthens the possi-
bility that targeting these immunological and inﬂammatory
pathways may represent another effective therapeutic approach to
preventing epileptic seizures.3.1. Limitation of the study
All animals were pretreated, so it is hard to extrapolate to the
clinical scenario where treatment would most likely be most ef-
fective afterward. This can be made use of in future experiments
where the effect of tested drugs is monitored following the in-
duction of SE.4. Experimental procedure
4.1. Materials
4.1.1. Test drugs
Lithium Chloride (Powder), Dexamethasone (4 mg/ml), and
Pilocarpine HCl (Sigma-Aldrich, MO, USA), Atropine Sulfate (1 mg/
1 ml ampoule) (CDM Lavoisier, Paris, France). Methotrexate (5 mg/
3 ml) (VHB Life Science Inc. India). Diazepam (Valium 5 mg/ml)
(Roche, New Jersey, USA). Celecoxib (Celebrex 100 mg capsule)
(Pﬁzer, New York, USA). Azathioprine (Imuran 50 mg tablet) (As-
pen, Australia). Sodium Valproate (Depakine 200 mg tablets) (Sa-
noﬁ Aventis, Paris, France), Ketamine HCl (100 mg/ml) (Woerden,
Holland).
4.1.2. Chemicals and kits
All chemicals used in this study were of analytical grade. The
kits used in this study are products of Sigma-Aldrich (Mybiosource
Inc., San Diego, California, USA).
4.1.3. Experimental animals
One hundred and forty adult male Wistar rats weighing
275725 g (King Fahd Research Centre, KAU, Jeddah) were used in
the study. The rats were housed in standard polypropylene cages
(ﬁve rats/cage) and maintained in a controlled environment at
2372 °C and 45–55% humidity, with a 12/12-h modiﬁed dark–
light cycle (light from 7:00 a.m. to 7:00 p.m.). They were allowed a
two-week accommodation before starting the experiment and
were provided with water and food ad libitum. Procedures invol-
ving animals and their care were conducted in accordance with
the approved guidelines of the UQU Animal Ethics Committee
(HAPO-02-K-012-2015-05-116). These guidelines comply with
national and international laws and policies regulating animal
research. Animals were examined twice daily for general body
conditions, activity, seizures, feeding, and injury.
4.2. 2. Methods
4.2.1. Induction of seizures by lithium-pilocarpine
Each rat received an intraperitoneal (ip) injection of LiCl
(127 mg/kg). On the following day, each rat was injected with
scopolamine methyl bromide (ip) (1 mg/kg) to alleviate the per-
ipheral effects of pilocarpine. Approximately 30 min later, they
were (ip) injected with pilocarpine hydrochloride (30 mg/kg)
(Glien et al., 2001). The consequential status epilepticus (SE) was
characterized by continuous, secondary generalized clonic and
clonic-tonic seizures starting 20–40 min following pilocarpine
administration. Seizure behaviors were recorded for rearing or
rearing with falling corresponding to stages 4–5 on the Racine
scale (Racine, 1972). Racine developed the scale by investigating
the relationship between electroencephalogram (EEG) changes
and the development of motor seizures. Only animals who de-
veloped stage 4–5 seizures were subjected to further investigation.
One, four, and eight hours following seizure onset, the rats were
(ip) injected with diazepam (15 mg/kg) to reduce their stress and
distress and to increase their survival rate. In control animals, pi-
locarpine was substituted with saline (Zheng et al., 2010).
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All surgeries were performed under anesthesia, and all efforts
were exerted to minimize animal suffering. Surgical anesthesia
was induced in rats by ketamine hydrochloride (80 mg/kg; Sigma-
Aldrich, MO, USA) and xylazine hydrochloride (10 mg/kg ip; Sig-
ma-Aldrich, MO, USA) (Kumar et al., 2013). EEG recordings were
performed using 8200-K2-SL: 2 EEG/1 EMG rat systems for sei-
zures (Pinnacle, USA). Forehead skin was excised under general
anesthesia to expose the skull and then cleaned and washed with
Ringer solution. Two trephine openings (2 mm in diameter),
frontal and occipital on each hemisphere, were made by drill bit
into the skull to expose the cortical surface. Two 1/800 EEG screw
electrodes with wire leads were gently screwed by a screwdriver
in each hemisphere to avoid any wear and tear to the cortical
surface. To avoid the drying of the cortical surface, Ringer solution
was used frequently for washing at room temperature (Sallam,
2012). Four electrodes were connected to the EEG headmount,
which was connected to the six-pin swivel connecting to the
ampliﬁer via a cable to a computer running 9037 Sirenias Seizure
Pro software.
The EEG recordings in the experimental session were taken
after a 10–15 min adaptation period and lasted for 10–15 min. The
frequency spectra of 12 s successive EEG recordings in the range of
3–15 Hz were analyzed on the compatible computer.
4.2.3. EEG amplitude
4.2.3.1. Signals recorded from the skull surface. In each group, the
amplitude (mV) and frequency (Hz) of the EEG responses were
measured during the 10–15 min recordings. Settings for seizure
detection were as follows: seizure duration, 42 s; minimum fre-
quency, 3 Hz; the length of EEG kept before and after each seizure
was 0.5 min (Abdullah and Raﬁqul Islam, 2012; Lehmkuhle et al.,
2009).
4.3. Blood and brain collection
4.3.1. Serum preparation
At the end of the experiment, rats were anesthetized with
ether. Blood samples were drawn from the retroorbital venous
plexus before being sacriﬁced at 10 a.m. Samples were collected in
vacutainer tubes and centrifuged for 15 min at 1500 g under
cooling. The resulting supernatant serumwas immediately divided
into 0.5 ml aliquots, transported at 20 °C, and stored at 80 °C
until the biochemical analyses could be performed (Balosso et al.,
2005).
4.3.2. Brain preparation
Rats were sacriﬁced by decapitation, and their brains were
removed 24 h (Arisi et al., 2015) after the induction of SE and after
EEG recordings and blood samples were collected. Forebrains were
dissected out and the cerebella were discarded. They were
weighed and then homogenized immediately using a handheld
homogenizer (CAT-SHM2; USA) in a known volume of ice-cold,
phosphate-buffered saline (Sigma-Aldrich) (0.01 M phosphate-
buffered saline; NaCl 0.138 M; KCl 0.0027 M/l pH 7.4) at 25 °C. The
homogenates were centrifuged for 15 min at 50,000 rpm and
stored at 80 °C for inﬂammatory mediators’ analyses the next
day (Rabuffetti et al., 2000).
4.4. Measurements of inﬂammatory mediators
Quantitative measurements of rat interleukin 1-ß (IL-1ß), in-
terleukin 6 (IL 6), prostaglandin E2 (PGE2), heat shock protein 70
(HSP70), transforming growth factor β2 (TGF-β2), and interferon
gamma (IFNγ) were carried out using commercially available
enzyme-linked immunosorbent assay (ELISA) kits supplied bySigma-Aldrich and Mybiosource Inc. (San Diego, California, USA)
and according to the manufacturers’ instructions. Each sample was
assayed in duplicate, and the mean value was calculated.
4.5. Statistical methods
Data were analyzed using SPSS (Version 18.0). All values are
expressed as mean7SD. Analysis of variance (ANOVA), followed
by multiple comparisons using Scheffe's test, were used. In all
tests, Po0.05 was considered statistically signiﬁcant.Funding
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